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Background: Bacterial infections have been assumed to worsen multiple sclerosis (MS) disease symptoms and to
lead to increased neurodegeneration. However, the underlying biological mechanisms for these effects are complex
and poorly understood. Here, we assessed the disease-modulating effects of chronic infection with Staphylococcus
aureus, a common human pathogen, on the clinical course and the extent of neurodegeneration in experimental
autoimmune encephalomyelitis (EAE), an animal model of MS.
Methods: To conduct this study, we established a persistent chronic infection in female brown Norway rats by
inoculating Staphylococcus aureus (S. aureus) bacteria in a subcutaneously implanted tissue cages.
Results: In this study, we observed that the introduction of a localized S. aureus infection during the subclinical
phase of EAE induced a chronic systemic inflammatory response, consisting of increased T- and B-cell counts and
systemic production of proinflammatory cytokines. Unexpectedly, the S. aureus infection completely prevented the
development of clinical EAE, and markedly reduced inflammatory infiltration and demyelination of the optic nerve,
while it increased the number of surviving retinal neurons. Using a S. aureus strain that lacked the extracellular
adherence protein (Eap), we determined that the extracellular adherence protein is at least partially responsible for
the inhibitory effect of S. aureus infection on autoimmune inflammation of the central nervous system.
Conclusions: Our results demonstrate for the first time that chronic infection with S. aureus has a beneficial effect on
EAE, indicating a dual role of infection in the pathogenesis of MS. We also showed that secretion of Eap by S. aureus
plays a major role in preventing autoimmune inflammation of the CNS. Moreover, we identified Eap as a factor
responsible for this protective effect.
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Multiple sclerosis (MS) is an autoimmune inflammatory
demyelinating disease of the central nervous system
(CNS), which often manifests with optic neuritis in its
early phase. Although the exact cause of this highly com-
plex disease is still unknown, genetic and environmental
factors are thought to be involved in disease initiation and* Correspondence: k.hein@uni-goettingen.de
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unless otherwise stated.pathogenesis [1]. A genome-wide study revealed an over-
representation of immunologically relevant genes in MS
patients [2]. However, the high rate of discordance in
monozygotic twins [3] and data from migration studies
indicate that environmental factors play an equal or
even more important role than genes in the pathogenesis
of MS.
Previous experimental and clinical studies demonstrated
that bacterial and viral infections can trigger and aggravate
autoimmune diseases [4-8]. Paradoxically, some microor-
ganisms seem to prevent MS [9-11]. Thus, there is ongoingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Experimental timeline. Tissue cage (TC) implantation
and fluorogold (FG) injection was done 2 to 3 weeks prior to
myelin oligodendrocyte glycoprotein (MOG) immunization. Agar
was injected into the TC 2 days before immunization. Injection
of Staphylococcus aureus (S. aureus) or saline was performed on
day 4 postimmunization (pi). Animals were followed until day 8 of
experimental autoimmune encephalomyelitis (EAE) or day 21 pi in case
of clinically healthy animals. To monitor the infection, blood samples
were taken throughout the whole experiment. Tissue was harvested
from the optic nerve for histopathological analysis; retina was
flat-mounted for quantification of retinal ganglion cells. Tissue
cage fluid (TCF) was checked for the presence of bacteria.
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esis of MS. Moreover, the underlying biological pro-
cesses, especially the association of systemic infection
and neurodegeneration, a major histopathological correl-
ate of disability in MS patients, are poorly understood.
Given the complexity of the interplay between infection
and autoimmunity, the majority of the knowledge stems
from animal studies in experimental autoimmune enceph-
alomyelitis (EAE), an animal model of MS.
In our present study, we induced EAE by immunization
with myelin oligodendrocyte glycoprotein (MOG). Al-
though the extent of spinal cord lesions in this model
shows a certain variability, active immunization of female
brown Norway (BN) rats with MOG leads to optic neuritis
with acute axonal degeneration of the optic nerve (ON)
and consecutive apoptosis of retinal ganglion cells (RGCs)
in 90% of the animals [12-15]. Therefore, this EAE model
provides a unique tool for investigating the morphological
changes in neuronal cell bodies and in axons during neu-
rodegeneration of the optic nerve.
Staphylococcus aureus (S. aureus) is a harmful pathogen
in both hospital- and community-associated infections
[16]. Locally applied S. aureus in implanted tissue cages
have been found to induce persistent chronic systemic in-
fections in animals [17]. In this study, we combined a
newly established chronic S. aureus infection model with
MOG-induced EAE in BN rats to investigate the impact
of chronic systemic infection on the clinical course of MS
and neurodegeneration in an animal model of MS.
Methods
Rats
Female brown Norway rats 8 to 10 weeks of age were used
in all experiments. They were obtained from Charles River
(Sulzfeld; Germany) and kept under environmentally con-
trolled and pathogen-free conditions. All experiments
involving animal use were performed in accordance with
the relevant laws and institutional guidelines. These exper-
iments have been approved by the local authorities of
Braunschweig, Germany.
Bacterial inoculum preparation
The S. aureus strains ATCC 29213 (kindly provided by
Raimund Lugert from the Department of Microbiology,
University of Goettingen; Germany), Newman ATCC
25904 [18] and the extracellular adherence protein (Eap)
deficient strain of ATCC 25904, AH12 [19] (kindly pro-
vided by Markus Bischoff from the Institute for Medical
Microbiology and Hygienie, University of Saarland; Germany)
were used in these experiments. A single colony of the re-
spective S. aureus strain was inoculated into brain heart
infusion medium and incubated for 20 hours at 37°C in a
shaking incubator. Afterwards, 50 μl of the bacterial cul-
ture grown for 20 hours were inoculated into 10 ml offresh brain heart infusion medium and again incubated at
37°C in a shaking incubator. Bacteria were harvested after
6 hours of incubation at the time when the bacterial cul-
ture reached the log phase of growth. Bacterial con-
centrations were determined by quantitative plating on
blood agar plates, and aliquots were kept at −80°C until
further use.
Retrograde labeling of retinal ganglion cells
Retrograde labeling of retinal ganglion cells (RGCs) and tis-
sue cage implantation was done during a single anesthesia,
2 to 3 weeks prior to MOG immunization. Rats were anes-
thetized by intraperitoneal injection of ketamine (Ketanest
10; 0.95 ml/kg; Atarost, Twistringen; Germany) and xyla-
zine 2% (0.25 ml/kg; Albrecht, Aulendorf; Germany) and
positioned in a stereotaxic frame. The skin was incised
mediosagittally, and holes were drilled into the skull above
each superior colliculus (6.8 mm dorsal and 2 mm lateral
from bregma). 2 μl of fluorescent dye fluorogold (5%
in distilled water; Fluorochrome, Englewood, CO) were
injected into both superior colliculi. After that, tissue cage
implantation was performed.
Experimental setup and timeline
Two experiments with a total of 62 animals were carried
out (Figure 1). Tissue cage implantation was performed
in all animals. Two to three weeks after the tissue cage
implantation and retrograde labeling of RGCs, 400 μl of
2.3% semi-solid agar was injected into the tissue cage
using a 27G needle (BD Eclipse, Heidelberg; Germany)
in order to enable persistent infection throughout the
course of the experiment by providing extra surface area
for the growth of bacteria. Before the agar injection, tis-
sue cage fluid (TCF) was obtained percutaneously from
all animals and checked for sterility by plating on blood
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if they had contaminated TCF. Two days after the agar
injection into the tissue cage, MOG-immunization was
done and considered day zero of immunization.
A rapid neurodegeneration occurs already in the pre-
clinical phase of EAE [14], which causes the failure of
most of therapeutic interventions, when applied at later
time points during the disease course [15,20]. Therefore,
infection was performed on day 4 postimmunization (pi) to
elucidate whether infection modulates the course of EAE
and has any influence on the neurodegeneration in this ani-
mal model. In the first experiment (n = 36), one animal
group was infected with a wild-type strain of S. aureus
(ATCC 29213). The corresponding control group received
saline. To prove our hypothesis of the anti-inflammatory
effect of Eap, animals (n = 26) were randomized into the
three different groups. One group was infected with the
wild-type S. aureus strain (ATCC 25904). The second
group was infected with the S. aureus strain deficient for
Eap (AH12). The corresponding control group received
saline. Animals were followed until day 8 after clinical
manifestation of the disease (EAEd8) or day 21 pi in case
of clinically healthy animals. At the end of the experiment,
TCF was obtained percutaneously from all (infected and
noninfected) animals. TCF was checked for the presence
of bacterial colonies by plating on blood agar plates.
Tissue cage preparation and implantation
Rigid polytetrafluoroethylene (teflon) tissue cages (internal
and external diameter of 8 and 10 mm respectively, length
25 mm) perforated by around 100 regularly spaced holes
(diameter 1 mm) containing two polymethylmethacrylate
(PMMA) cover slips per tissue cage, sealed at both ends
with a suture (Ethicon, Norderstedt; Germany), were used
as a foreign body implant. A cutaneous incision in the left
flank was made under anesthesia, and one autoclaved tis-
sue cage was subcutaneously implanted under sterile con-
ditions into each animal.
Induction of chronic infection
Infection was performed by injection of 200 μl of bac-
terial culture diluted in 0.9% NaCl (saline) (B. Braun,
Melsungen; Germany) containing 2 × 107 colony forming
units (CFU) of the respective S. aureus strain into the agar
of the tissue cage. Control animals received 200 μl saline
into their tissue cage.
Induction and evaluation of experimental autoimmune
encephalomyelitis
Rats were anesthetized by inhalation anesthesia with
isoflurane (Abbott, Wiesbaden; Germany) and injected
intradermally at the base of the tail with a total vol-
ume of 200 μl inoculum, containing 50 μg recombin-
ant rat MOGIgd (kindly provided by C. Stadelmann,Institute of Neuropathology, Goettingen; Germany) in sa-
line emulsified (1:1) with complete Freund’s adjuvant
(CFA; Sigma-Aldrich, St. Louis, MO) containing 200 μg
heat-inactivated Mycobacterium tuberculosis (strain H 37
RA; Difco Laboratories, Detroit, MI). Rats were scored for
clinical signs of EAE and were weighed daily. This score
reflects the amount of spinal cord lesions and does not in-
clude visual symptoms or correlate with the severity of
optic neuritis ([15,21]. The signs were scored as follows:
grade 0, no symptoms; grade 0.5, distal paresis of the tail;
grade 1, complete tail paralysis; grade 1.5, paresis of the
tail and mild hind limb paresis; grade 2.0, unilateral severe
hind limb paresis; grade 2.5, bilateral severe hind limb par-
esis; grade 3.0, complete bilateral hind limb paralysis;
grade 3.5, complete bilateral hind limb paralysis and par-
esis of one front limb; grade 4, complete paralysis (tetra-
plegia), moribund state, or death.
Leukocyte count
To monitor the systemic infection leukocytes were counted
in the peripheral blood every second day until day 8 after
MOG immunization and then at intervals of 3 days until
day 20 pi. Blood samples were taken sublingually after
inhalation anesthesia with isoflurane. A total of 10 μl
of blood sample was diluted in 190 μl of 4% glacial




For Western blot analysis, 6 animals (n = 3 for each group)
were sacrificed on day 3 postinfection. Blood samples were
collected by cardiac puncture using 18 G needle (BD
Eclipse, Heidelberg; Germany) from S. aureus infected
and noninfected animals and placed on ice for 30 minutes.
Serum was separated from the whole blood by centrifu-
ging it at 3,500 rpm for 10 minutes, and protein concen-
tration of the serum was measured using BCA assay kits
(Thermo Fisher Scientific Inc; U.S.A). Equal amount
of protein from each sample was subjected to 12%
SDS-PAGE and transferred onto a nitrocellulose mem-
brane. The membrane was blocked with 5% nonfat dry
milk in Tris-buffered saline containing 0.1% Tween 20
(TBST) for 1 hour at room temperature. Incubations with
rabbit anti-Eap antibody (1:1500; Cat# ab92982, Abcam;
U.K.), was performed overnight at 4°C. After being
washed, the membrane was incubated with a horseradish
peroxidase-conjugated appropriate secondary antibody
(1:5,000 Jackson Immuno Research Europe; U.K.) in 5%
nonfat dry milk in TBST for 1 hour at room temperature,
and immune-reactive proteins were detected using the en-
hanced chemiluminescence method (ECL; Amersham).
Also, 3 μg of purified Eap (a gift from Markus Bischoff,
University of Saarland, Germany) was used as positive
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ing of proteins.
Histopathology and immunohistochemistry
Retinas were removed for counting of RGCs, and
paraformaldehyde-fixed paraffin-embedded optic nerves
(ONs) were taken for histopathological evaluation. After
perfusion of rats with 4% PFA, ONs were post-fixed in 4%
PFA for 24 h and embedded in paraffin. Histological evalu-
ation was performed on 2 μm thick slices stained with Luxol
Fast Blue to assess demyelination. Photos of vertical sections
were taken using an AxioCam MR Microscopy camera
(Zeiss, Göttingen; Germany). The images were processed
using Zeiss AxioVision 4.2 software to evaluate the demyeli-
nated area as a percentage of the whole ON cross section.
Immunohistochemistry was performed on paraffin embed-
ded ON cross sections representing three different levels
of an ON. ED1 macrophages/ activated microglia (AbD
Serotec Cat# MCA341R RRID: AB_2291300), were detected
in cross sections using avidin-biotin detection. Spleen
sections served as positive control for ED1 staining. ED1
positive cells were evaluated using the following score: 0, no
labeled cells; 1, a few ED1 positive cells (number countable,
infiltration of less than 10% of the ON cross-section area); 2,
infiltration of less than 10% of the ON cross section area
with ED1 positive cells in at least one of the three cross
sections of an ON, number of ED1 positive cells not count-
able; 3, infiltration of 10 to 50% of the ON cross section area
with labeled ED1 positive cells in at least one of three cross
sections of an ON; 4, infiltration of 50 to 80% area of the
ON cross-section area in at least one of the three cross
sections of an ON; and 5, infiltration of more than 80% of
the ON cross section area in at least one of the three cross
sections of an ON.
Quantification of T cell infiltrates in optic nerve
CD3 staining for assessment of infiltration of CD3-positive
cells across the blood–brain barrier was performed on
0.5 μm thick cross section slices of paraffin-embedded ONs
using anti-CD3 antibody (Biozol Cat# BZL03543 RRID:
AB_2313498). CD3-positive cells were detected by biotin-
avidin detection. Spleen sections served as positive control
for CD3 staining. To quantify T-cell infiltrates in the ON,
we used tissue studio that is based on Cognition Network
Language (Definiens Cognition Network Technology®, De-
finiens Developer XD software, Munich; Germany) In
brief, CD3-stained sections were scanned using the 3D
Histech 250 Flash slide scanner at 200-fold magnification.
The area of interest (optic nerve) was first detected
from the background by the color spectrum. After
segmentation, nuclei and CD3-positive cytoplasm were
discriminated. Within each area of interest, the total num-
ber of CD3-positive cells was calculated and expressed as
cells/mm2.Quantification of axonal densities in optic nerve
To quantify axonal densities in the ON, 0.5-μm thick
cross section slices of ONs were stained by Bielschowsky
silver impregnation staining to visualize axonal struc-
tures. Automated quantification of axonal densities was
performed on high magnification pictures (100x) apply-
ing a custom-programmed script in Cognition Network
Language based on the Definiens Cognition Network
Technology® platform (Definiens Developer XD software,
Munich; Germany). Briefly, the programmed script first
discriminates between tissue and background (no tissue)
by spectral difference detection. Subsequently, the area of
detected tissue (region of interest, ROI) was calculated
and ‘axonal structures’ within this ROI were detected
based on their dark black color. To discriminate between
nucleoli of inflammatory cells and axons (which both
structures are stained black in Bielschowsky silver impreg-
nation) only black structures without a faint brown-
stained circumference (nucleus) were further classified as
axonal structures. In a next step, multiple axons in direct
contact with each other were further split into the corre-
sponding individual axons if the splitting improved the el-
liptic shape of an axon. Within each area ROI, the total
number of axons was calculated. The density of axons in
each ON was measured in at least nine standardized
microscopic fields of each ON. The mean axon density
was calculated for each ON and expressed as axons/mm2.
Quantification of retinal ganglion cell density
Retinae were dissected, flat-mounted on glass slides, and
examined by fluorescence microscopy (Zeiss Axioplan 2)
using a DAPI filter (315/395 nm). Retinal ganglion cell
densities were determined by counting labeled cells in
three areas (62,500 μm2 each) per retinal quadrant at
three different eccentricities of 1/6, 3/6, and 5/6 of the
retinal radius. Cell counts were performed by two inde-
pendent investigators following a blinded protocol.
Flow cytometry
Flow cytometry for lymphocyte counting was performed
in blood on day 4 pi prior to infection and 2 days after in-
fection at the time when the leukocyte counts reached
their peak. In brief, 100 μl blood taken sublingually was
collected in 250 μl of 5 mM EDTA prepared in isotonic
PBS. Samples were washed once with PBS, and RBC lysis
buffer (0.1 M ammonium chloride in PBS) was added in
each sample. Samples were left at 4°C for 10 minutes and
washed once with PBS. A total of 100 μl of FACS buffer
(PBS + 1% BSA + 0.1% NaN3) containing anti-CD45RA
(BioLegend Cat# 202307 RRID: AB_314010) and anti-CD3
(BioLegend Cat# 201408 RRID: AB_893304) antibodies
were added in each samples at a dilution of 1:200. Incuba-
tion was done for 45 minutes at 4°C in the dark. The cells
were washed once with PBS and re-suspended in 200 μl of
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was performed by four-color flow cytometry using a
FACSCalibur and FacScan software (BD; Goettingen;
Germany).
Luminex assay
A Luminex assay kit (Bio-Plex Pro™ Rat Cytokine Th1/Th2
Assay #171-K1002M), containing premixed coupled mag-
netic beads and detection antibodies for detecting 12 rat
cytokines (IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12, IL-13, TNF-alpha, INF-gamma, GM-CSF)
was used for measurement of cytokine concentrations in
serum samples collected at the end of the experiment.
The total number of animals used in this cytokine assay was
25 (n = 11 infected with wild-type strain of S. aureus (ATCC
25904); n = 9 infected with Eap-deficient of S. aureus
(AH12); n = 5 noninfected control). Quantification of cyto-
kines was performed according to the manufacturer’s in-
structions. Measurement was performed by using a
Bioplex 200-system based on the Luminex xMAP-technology
(Bio-Rad, Hercules, CA, USA). The signal detection
occurred using the Bioplex 200-system and the Bioplex
Manager Software version 6.0.
Statistical analysis
Data are presented as means ± SEM. Student’s t-test was
used to analyze differences between two animal groups.
Multiple comparisons were statistically evaluated by
one-way ANOVA using Prism 5 (GraphPad Software).
Mann–Whitney U test was used for the analysis of the
EAE score (SPSS, IBM). A P value of <0.05 was consid-
ered to be statistically significant.
Results
Local infection with Staphylococcus aureus leads to
persistent systemic inflammation
To confirm the persistent local infection in the animals,
we collected tissue cage fluid (TCF) from all animals
under sterile conditions at the end of the experiment
and plated the TCF on blood agar plates. TCF obtained
from infected animals contained a high number of bac-
teria (S. aureus), whereas no bacterial growth was ob-
served in TCF from noninfected control animals. Due to
the semisolid consistency of TCF, which is probably due
to the presence of agar, dilutions for a more exact deter-
mination of bacterial numbers were not possible. To ensure
that local application of bacteria induced systemic inflam-
mation, leukocytes were counted in peripheral blood sam-
ples until day 20 pi (corresponding to day 16 postinfection).
Here, we observed that the leukocyte counts in infected an-
imals (18475 ± 685/μl; n = 12; Figure 2A) were significantly
elevated 2 days after infection compared to noninfected
control animals (9000 ± 305/μl; n = 11; P <0.001; Figure 2A).
Afterwards, leukocyte counts decreased in the infectiongroup, but remained significantly elevated compared to
the control group until day 20 pi (12457 ± 1219/μl versus
8583 ± 936/μl, P = 0.03; Figure 2A).
An anti-inflammatory effect of Eap secreted by S. aureus
was demonstrated in chronic infections as well as in auto-
immune disease models [22-24]. Therefore, we hypothe-
sized that this protein is responsible for the protective
effects of S. aureus infection in EAE. To prove our hy-
pothesis, a second set of experiments was performed by
including a group of animals infected with a S. aureus
strain deficient for Eap. In this experiment, leukocyte
counts were significantly elevated two days after infection
in the animals infected with the wild-type strain (17236 ±
742/μl; n = 11; P <0.001) and in the animals infected with
the Eap-deficient strain (18575 ± 585/μl; n = 10; P <0.001)
in contrast to the control group (9940 ± 527/μl; n = 5)
(data not shown). We did not observe any significant dif-
ference between the leukocyte counts of the two infection
groups at any time point during the whole course of the
experiment.
Infection with Staphylococcus aureus enhances T- and
B-cell counts in peripheral blood
Flow cytometry was performed to assess the B- and T-cell
counts in peripheral blood on day 4 post immunization
(pi) (directly prior to infection) and day 6 pi (correspond-
ing to day 2 after the infection). B-cell counts (Figure 2B;
n = 4 in each group) were significantly increased in the
S. aureus-infected group (67 ± 10.55%; P = 0.002) on day 6
pi compared to day 4 pi. In contrast, no significant change
in B-cell counts was observed in noninfected animals on
day 6 pi compared to day 4 pi. T-cell counts (Figure 2C;
n = 4 in each group) increased significantly in both groups
on day 6 pi compared to day 4 pi, however, the increase
was more prominent in infected than in noninfected ani-
mals (117 ± 19.38% versus 45 ± 8.32%; P = 0.013; Figure 2C).
These results show that infection with S. aureus induces
both B-cell and T-cell response in peripheral blood.
Infection with Staphylococcus aureus leads to increased
concentrations of pro-inflammatory cytokines in the
systemic circulation
Among the 12 cytokines measured by Luminex assay in
serum samples collected at the end of the experiment,
we observed differences in the levels of IFN-gamma,
IL-6 and TNF-alpha. More detailed, levels of IFN-gamma
(Figure 3A) was significantly increased in animals infected
with the wild-type bacteria (411.4 ± 28.37 pg/ml) com-
pared to animals infected with the Eap-deficient strain
(303.9 ± 39.08 pg/ml; P = 0.035) and compared to nonin-
fected control animals (284.9 ± 46.49 pg/ml; P = 0.029).
Serum levels of IL-6 (Figure 3B) were also significantly
elevated in the group infected with the wild-type S.
aureus bacterium (926.6 ± 57.27 pg/ml) compared to
Figure 2 Leukocyte counting and flow cytometry. Leukocyte counts (A) were performed in peripheral blood of infected and noninfected
myelin oligodendrocyte glycoprotein (MOG)-immunized animals. The leukocyte count was found to be significantly higher in the infected group.
Data are represented as means ± SEM of all animals from each group (n = 12, infected; n = 11, noninfected). Flow cytometry was performed in
peripheral blood to assess B- and T-cell populations in animals infected with S. aureus and noninfected control group on day 4 postimmunization
(pi) (prior to infection) and on day 6 pi (corresponding to day 2 postinfection). B- (B) and T-cell (C) populations were substantially increased in
infected animals 2 days after infection. Data are presented as means ± SEM. (n = 4 in each group; *P <0.05; **P <0.01; ***P <0.001).
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(704.4 ± 75.48 pg/ml; P = 0.028) and the control group
(668.7 ± 119.1 pg/ml; P = 0.042). A tendency towards
higher serum levels of TNF-alpha (Figure 3C) was ob-
served in the animals infected with wild-type S. aureus
bacteria (330.7 ± 82.96 pg/ml) compared to the group in-
fected with Eap-deficient S. aureus (233.2 ± 51.44 pg/ml;
P = 0.35) and the noninfected control group (169.9 ±
30.89 pg/ml; P = 0.22). The level of other cytokines (IL-1
alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 and
GM-CSF) did not change significantly.Figure 3 .Luminex assays. Luminex detection assays indicated a
significant increase of IFN-gamma (A) and IL-6 (B) in blood of animals
infected with Staphylococcus aureus wild-type strain. TNF-alpha showed
a tendency towards an increase of level in the group infected with the
wild-type S. aureus (C) (n = 11, wild-type; n = 9, Eap-deficient (mutant);
n = 5, saline treated (control); *P <0.05).Staphylococcus aureus infection prevents the
manifestation of clinical symptoms and suppresses
disease activity in myelin oligodendrocyte glycoprotein
induced experimental autoimmune encephalomyelitis
Animals were infected with S. aureus on day 4 after
immunization to avoid interference with the initiation of the
autoimmune response. Around day 13 after immunization,
6 of the 14 placebo-infected animals developed clinical
symptoms while infection with wild-type S. aureus (ATCC
29213) prevented the clinical manifestation of EAE in all
the infected animals. The mean cumulative score differed
significantly between the group infected with S. aureus
and the respective control group (P = 0.047; Figure 4).
Concerning the clinical manifestation of the disease, a
similar result was observed in the experiment in which
the Eap-deficient strain and the corresponding wild-type
strain were used. Although no clinical signs of EAE were
observed in the group infected with S. aureus (ATCC
25904) or in the group infected with the Eap-deficient
strain (AH12) of S. aureus, animals of the group infected
with Eap-deficient S. aureus displayed level of histopatho-
logical abnormalities (see below). However, noninfected
control animals were severely affected with a mean EAE
score of 2.4 ± 0.36 (n = 5; P <0.001; data not shown here)
at the end of the experiment.
Infection with Staphylococcus aureus reduces
neuropathological damage of the optic nerve and
increases retinal ganglion cells survival after acute optic
neuritis
At day 8 of clinical disease or at day 21 after immunization
in the absence of manifest disease, we determined the ex-
tent of demyelination of the optic nerves (ONs) by Luxol
Fast Blue staining. Additionally, we performed immuno-
histochemistry for ED1 macrophages/microglia and CD3+
T-lymphocytes to assess the extent of inflammatory
Figure 4 Clinical score. Infection with wild-type Staphylococcus
aureus (ATCC 29213) on day 4 postimmunization (pi) prevented
disease onset in myelin oligodendrocyte glycoprotein induced
experimental autoimmune encephalomyelitis (MOG-EAE). Data
represented as means ± S.E.M. of the daily score. The clinical score
represents spinal cord lesions. Presence of optic neuritis is not included
(n = 16, infected; n = 14, noninfected).
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Bielschowsky’s silver impregnation. For each staining, ON
cross sections of three different levels were evaluated.
In the animals infected with the S. aureus wild-type
strain, we observed significantly less demyelination in
ON cross sections (28.08 ± 7.94%; Figure 5A, I; n = 16)
compared to noninfected control animals (67.41 ± 8.17%;
P = 0.0011; Figure 5B, I; n = 14). Analysis of inflamma-
tory infiltrates with ED1 staining revealed a substantially
lower infiltration by macrophages and activated micro-
glia in the infected group (1.22 ± 0.33; Figure 5C, J; n = 16)
compared to the control group (3.41 ± 0.35; P <0.001;
Figure 5D, J; n = 14). Quantification of CD3+ cells re-
vealed that only the minority of infiltrating cells were
CD3+ T-lymphocytes. At day 21 after immunization,
numbers of CD3+ cells were found to be significantly
lower in the S. aureus infected group (10.09 ± 2.88/mm2;
Figure 5E, K; n = 16) in comparison to the noninfected
control group (34.46 ± 6.39/mm2; P <0.001; Figure 5F, K;
n = 14). Using Bielschowky’s silver impregnation, we ob-
served a higher axonal density in infected animals (129700 ±
14580/mm2; Figure 5G, L; n = 16) compared to noninfected
control animals (51260 ± 12810/mm2; P <0.001; Figure 5H,
L; n = 14).
To evaluate the impact of infection on neurodegenera-
tion, numbers of surviving RGCs, the neurons that form
the axons of the ON, were counted on day 8 of MOG-EAE.
Previously, we have shown that in healthy BN rats sham-
immunized with complete Freund’s adjuvant (CFA), 2730 ±
145 RGCs/mm2 were detectable (mean ± SEM; n = 8) [13].
In our present study, the mean RGC density in noninfected
control animals at day 8 of MOG-EAE dropped to 1085 ±
85.7/mm2 (Figure 5M; n = 14). In contrast, RGC density ininfected animals was significantly higher (1449 ± 64.60/
mm2, P = 0.002; Figure 5M; n = 20). For RGCs counts, n in-
dicates the number of eyes.
Extracellular adherence protein is present in serum of
animals infected with Staphylococcus aureus
To investigate the presence of Eap in the peripheral
blood circulation of infected animals, Western blot ana-
lysis was performed in serum samples collected from
rats infected with wild-type S. aureus as well as from
MOG-immunized noninfected control animals. Western
blot analysis revealed the presence of Eap in the circula-
tion of the animals infected with S. aureus (Figure 6). No
Eap was detected in the serum samples collected from the
MOG-immunized noninfected control animals (Figure 6).
The protective effect of wild-type Staphylococcus aureus
infection on optic neuritis is reduced in the group
infected with respective extracellular adherence
protein-deficient strain
In further experiments, an Eap-deficient S. aureus strain
and the respective wild-type S. aureus strain were used
for infection of the animals. In these experiments, we
observed significantly less demyelination (Figure 7A) in
wild-type S. aureus infected animals (22.77 ± 8.46%; n = 11)
in comparison to both Eap-deficient infected (53.53 ±
10.56%; P = 0.027; n = 10) and control animals (100 ±
0%; P <0.001; n = 4). Accordingly, the extent of inflamma-
tion accessed by ED1 staining (Figure 7B) was significantly
lower in the group infected with wild-type S. aureus bac-
teria (1.24 ± 0.39; n = 11) in comparison to the group in-
fected with Eap-deficient bacteria (2.73 ± 0.40; P = 0.012;
n = 10) and the noninfected control group (4.66 ± 0.15;
P <0.001; n = 4). CD3+ T-Lymphocyte counts revealed
significantly lower numbers of CD3+ cells (Figure 7C)
in animals infected with wild-type S. aureus (7.6 ± 3.75/
mm2; n = 11) in comparison to the animals infected with
Eap-deficient bacteria (39.81 ± 10.37/mm2; P = 0.004; n =
10) and the control group (55.2 ± 25.8/mm2; P = 0.007;
n = 4). No significant difference was observed in CD3+
cell counts between the animals infected with Eap-
deficient S. aureus bacteria and the noninfected control
group (P = 0.5). Bielschowsky’s silver impregnation was
performed to assess the axonal pathology of the optic
nerve (Figure 7D) and revealed that the animals infected
with wild-type bacteria showed a higher number of axonal
counts (173500 ± 18220/mm2; n = 11) in comparison to
the group infected with Eap-deficient bacteria (73953 ±
14500/mm2; P <0.001; n = 10) and noninfected control
animals (16670 ± 1938/mm2; P <0.001; n = 4). The RGC
density was higher in the animal group infected with
the wild-type strain (1447 ± 66/mm2; Figure 7E; n = 18)
compared to animals infected with the Eap-deficient
strain (1001 ± 65/mm2; P <0.001; Figure 7E; n = 13) and
Figure 5 Optic nerve (ON) histopathology and retinal ganglion cell (RGC) counts. A and B: Representative Luxol Fast Blue-stained cross
sections of ONs of a wild-type Staphylococcus aureus infected rat (A) showed only small areas of demyelination, with mainly intact myelin (blue);
in contrast, a cross section from a noninfected control animal (B) showed extensively demyelinated areas (purple). C and D: Representative
examples of the substantially higher number of ED1 macrophages/activated microglia detected in the ON of a noninfected control animal (D),
compared with an animal infected with wild-type S. aureus (C). E and F: representative images for CD3+ T-lymphocyte counts, which were noted
higher in the optic nerve of the animals from control group (F), whereas CD3-positive cells were hardly present in the optic nerve of the group
infected with bacteria (E). G and H: Bielschowsky’s silver impregnation of ON cross sections revealed a higher density of axons on experimental
autoimmune encephalomyelitis (EAE) day 8 in wild-type S. aureus infected animals (G) compared to noninfected control animals (H). I, J, K and L
represent the quantitative data for demyelination, ED1 score, CD3-positive cells and for axonal loss, respectively. M: Represents the quantitative data
for fluorogold labeled RGCs, which showed higher density in the animals infected with S. aureus compared to the noninfected control group. For
optic nerve histopathology, n = 16 infected, n = 14 noninfected; for RGC counts n = 20 infected; n = 14 noninfected, where n indicates the
number of eyes used for counting the RGCs; **P <0.01; ***P <0.001). Bar length for Luxol Fast Blue, ED1, CD3- = 100 μm, and for
Bielschowsky’s silver impregnation = 20 μm.
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Figure 7E; n = 9).
Discussion
Using a rat model of MOG-induced EAE, we have dem-
onstrated for the first time that chronic infection with S.
aureus prevents the onset of EAE and reduces the devel-
opment of histopathologic changes in the optic nerve.
Using an extracellular adherence protein (Eap)-deficient
strain of S. aureus, we showed that secretion of Eap by
S. aureus plays a major role in preventing inflammation
of the central nervous system (CNS).Peripheral infection has been shown to exacerbate the im-
mune response in experimental models of MS and in patients
[7,25-28]. However, investigations of the role of infection in
MS patients are complicated by the lack of a surrogate
marker of disease activity. The results of magnetic resonance
imaging (MRI) studies on the influence of peripheral infection
on the number of contrast-enhancing MS lesions as a
marker of disease activity are inconsistent [26,29]. Moreover,
reliable markers to assess neurodegeneration in MS patients
do not exist. For these reasons, much of the knowledge re-
garding the relationship between systemic infection and
autoimmunity in MS is derived from EAE model studies.
Figure 6 Western blot analysis. Western blot analysis showed the
presence of extracellular adherence protein (Eap) in the serum of
animals infected with wild-type S. aureus bacterium (Lane 5, 6 and 7).
No Eap was detected in the serum samples of the control animals
(Lane 2, 3 and 4). Purified Eap (Lane 1) was used as a positive control.
Ponceau staining was used as a loading control.
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the clinical course of the disease. These studies used bac-
terial compounds (for example, LPS, enterotoxins) [30-32]
rather than whole viable bacteria; thus, their results do
not accurately reflect the clinical situation of MS patients.
To our knowledge, this study is the first to investigate the
effects of chronic infection with viable bacteria in an EAE
model. By locally injecting a S. aureus strain, which is
pathogenic for humans, into a previously implanted tissue
cage, we established a stable chronic systemic infection in
BN rats. This infection model is advantageous because it
induces a mild infection that does not require antibiotic
treatment to keep the animals alive. In our study, two days
after the local application of the bacteria, corresponding
to day 6 after immunization, the systemic infection be-
came prominent as determined by increased leukocyteFigure 7 Optic nerve (ON) histopathology and retinal ganglion cell (R
reverted in the Eap-deficient strain. Quantitative data for extent of demyeli
(E). Animals infected with the wild-type strain of S. aureus (wild-type; n = 1
(control; n = 4); while for RGC counts (n = 18, wild-type; n = 13, mutant; n =
RGCs), (*P <0.05; **P <0.01; ***P <0.001).counts in peripheral blood. The rationale for the selected
infection time point came from experimental and clinical
studies suggesting that the subclinical phase of MS is the
‘at risk’ period with the greatest susceptibility to systemic
inflammation [7,33].
Infectious agents are known to rapidly expand the
pool of immune cells, including auto-reactive T-cells in
EAE and thus can contribute to the disease progression
[5,34,35]. In our study, we detected a substantial in-
crease of B- and T-cell counts in peripheral blood 2 days
after the inoculation of bacteria into tissue cages im-
planted in the animals. Moreover, significant elevation of
IL-6 and INF-gamma levels and a tendency to higher
levels of TNF-alpha in serum was observed after infec-
tion with the S. aureus wild-type strains at the end of
the experiment. However, at this time point the pro-
inflammatory cytokine pattern was not detected in ani-
mals that were infected with the Eap-deficient strain
compared to the control. Intriguingly, in spite of on-
going inflammation in the periphery the infection with
S. aureus prevented the onset of clinical EAE symptoms
and decreased the severity of autoimmune optic neuritis.
The entry of leukocytes into the CNS is considered an
early phenomenon in MS that induces blood-brain barrier
breakdown and neuroinflammation. The relevance of vas-
cular cell adhesion molecule 1 (VCAM-1) and intercellular
adhesion molecule (ICAM-1) for migration of lymphocytes
across the blood-brain barrier during EAE has been
shown in several experimental studies [36-38]. Although
the very late antigen-4 and vascular cell adhesion molecule
1 (VLA-4-VCAM-1) interaction predominantly mediates
the initial adhesion to the vessels, lymphocyte function-
associated antigen 1 and intracellular adhesion molecule-1GC) counts. The positive effect of S. aureus on optic neuritis was
nation (A), inflammation (B, C), axonal damage (D) and RGC counts
1), with the Eap deficient strain (mutant; n = 10) or treated with saline
9, control), n indicates the number of eyes used for counting the
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endothelial migration of T-cells [39,40].
S. aureus expresses anti-adhesive and antimigratory fac-
tors that specifically interfere with every step of host in-
flammatory cell recruitment [41]. A major anti-adhesive
protein of the S. aureus ‘secretable expanded repertoire
adhesive molecules’ (SERAM) is Eap, which is present in
97% of clinical isolates [42]. Eap interacts specifically with
endothelial ICAM-1, leading to inhibition of the ICAM-1-
integrin interaction [22]. The anti-inflammatory property
of Eap in autoimmune diseases has been found in EAE
and an animal model of psoriasis [24,40]. These observa-
tions led us to hypothesize that the anti-inflammatory ef-
fects of S. aureus infection in MOG-induced EAE are
mediated through Eap secretion. In our study, infection
with an Eap-deficient S. aureus strain led to increased in-
flammation, demyelination, and axonal damage in the
optic nerve when compared to animals infected with wild-
type S. aureus. However, histopathological analysis of the
optic nerve revealed that the anti-inflammatory property
of S. aureus infection was not completely abolished by the
lack of Eap. Moreover, the infection with the Eap-deficient
strain prevented the clinical manifestation of the disease
indicating that additional factors, such as enterotoxins
secreted by bacteria might be involved in the anti-
inflammatory effects of S. aureus. However, the dual
role of these enterotoxins has been observed in previous
EAE-studies [30,43-45].
Given the importance of ICAM-1 antagonism in dif-
ferent autoimmune diseases [46], Eap is believed to be
the most potent factor for inhibition of T-cell migration
into the CNS. This hypothesis is supported by our histo-
pathological evaluations, which revealed a substantial re-
duction in the number of lymphocytes in inflammatory
infiltrates obtained from the optic nerves of wild-type
S. aureus-infected animals. In our previous EAE studies,
we observed that a strong anti-inflammatory response is not
always sufficient to prevent neurodegeneration [12,15,47].
Although the increased neuronal and axonal survivals de-
tected in S. aureus-infected animals seemed to be related
to the anti-inflammatory properties of Eap, we cannot rule
out the possibility of direct neuroprotection by Eap. Fur-
ther studies are needed to clarify this issue.
Approval of immunosuppressive drugs for MS treat-
ment has progressed very rapidly in recent years. Thus,
the incidence of infections in MS patients and the prob-
lems associated with them are increasing. Our results
demonstrate, for the first time, that chronic S. aureus in-
fection has beneficial effects on EAE. Importantly, our
results do not trivialize the necessity for antibiotic treat-
ment of infections. As infections activate peripheral in-
flammatory events, they can induce a general immune
response in MS patients known as ‘sickness behavior’.
However, some factors released by bacteria seem tohave a beneficial effect on autoimmune inflammation
in the CNS.
Conclusions
Bacterial infections have been assumed to worsen MS
disease symptoms and to lead to increased neurodegen-
eration. In contrast, our results demonstrate for the first
time that chronic infection with S. aureus induces strong
peripheral systemic inflammation, but still prevented
clinical symptoms in an animal model of MS. Moreover,
S. aureus infection reduced autoimmune inflammation of
the CNS and reduced the severity of autoimmune optic
neuritis. Furthermore, using an Eap-deficient S. aureus
strain, we showed that secretion of Eap by S. aureus plays
a major role in preventing autoimmune inflammation of
the CNS. Infection with S. aureus also increased the num-
ber of surviving retinal ganglion cells and their axonal
counts, most likely via the anti-inflammatory properties of
Eap. However, further studies are needed to determine
whether Eap exerts a direct neuroprotective effect.
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